A Phase l/ll, Open Label, Dose-escalation Study of Varlilumab (CDX-1127) in Combination With Atezolizumab (MPDL3280A, Anti-PD-L1) in Patients With Advanced Cancer.

Trial Profile

A Phase l/ll, Open Label, Dose-escalation Study of Varlilumab (CDX-1127) in Combination With Atezolizumab (MPDL3280A, Anti-PD-L1) in Patients With Advanced Cancer.

Discontinued
Phase of Trial: Phase I/II

Latest Information Update: 22 Jun 2017

At a glance

  • Drugs Atezolizumab (Primary) ; Varlilumab (Primary)
  • Indications Bladder cancer; Breast cancer; Head and neck cancer; Malignant melanoma; Non-small cell lung cancer; Renal cell carcinoma; Urogenital cancer
  • Focus Adverse reactions; Therapeutic Use
  • Sponsors Celldex Therapeutics Inc
  • Most Recent Events

    • 15 Mar 2017 Status changed from recruiting to discontinued.
    • 14 Mar 2017 According to a Celldex Therapeutics media release, company has decided not to advance the varlilumab/Tecentriq combination studies in renal cell carcinoma to Phase 2, due to cost-containment.
    • 08 Aug 2016 According to a Celldex Therapeutics media release, enrollment has been completed in the phase I dose-escalation portion and the company anticipates to initiate the phase II portion of the study in renal cell carcinoma in the third quarter of 2016.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top